Ultra News

Lupin gets USFDA nod for scalp solution

Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd.

Calcipotriene Topical Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.

Lupin’s Calcipotriene Topical Solution, 0.005% (Scalp Solution) is the AT rated generic equivalent of Leo Pharmaceutical Products Ltd’s Dovonex Scalp Solution.

Calcipotriene Topical Solution, 0.005% (Scalp Solution) had annual sales of approximately USD 5.9 million in the US, it said.

Lupin manufacturers branded & generic formulations, biotechnology products and APIs, focusing on Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space.

It is the 6th largest generics pharmaceutical company by revenues.

The Company is the 4th largest pharmaceutical player in the US by prescriptions.